본문 바로가기
KERD
논문KCI 등재

Basic knowledge for counseling patients undergoing risk-reducing salpingo-oophorectomy

Chel Hun Choi|Jihye Kim
대한산부인과학회 (Korean Soceity of Obstetrics and Gynecology)|2024.07|Obstetrics & Gynecology Science|제67권 제4호|pp. 343-355|DOI 10.5468/ogs.24054

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

MenopauseBreast cancerEpithelial ovarian cancerBRCA mutationRisk-reducing salpingo-oophorectomy
주제분류산부인과학

초록

Significant progress has been made in the molecular diagnosis of cancer. It provides personalized medicine, including cancer diagnosis, prognosis, targeted therapy, and risk detection. These advances allow physicians to identify patients at risk for cancer before it develops and offer them an opportunity to prevent its development. Mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and 2) are one of the most well-known cancer-related gene mutations since actor Angelina Jolie shared her experience with genetic mutations and risk-reducing surgery in the media. In Korea, tests for germline BRCA1/2 mutations have been covered by insurance since May 2012 and the number of women of BRCA1/2 mutations has continued to increase over the past decade. Most carriers of BRCA1/2 mutations consider risk-reducing salpingo-oophorectomy (RRSO) resulting in early menopause and want to know the lifetime risks and benefits of RRSO. However, despite the increasing number of carriers of BRCA1/2 mutations, the counseling and management of patients requiring RRSO varies among physicians. This article provides basic knowledge on RRSO to help physicians comprehensively assess its risks and benefits and manage at-risk women.

Abstract

Significant progress has been made in the molecular diagnosis of cancer. It provides personalized medicine, including cancer diagnosis, prognosis, targeted therapy, and risk detection. These advances allow physicians to identify patients at risk for cancer before it develops and offer them an opportunity to prevent its development. Mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and 2) are one of the most well-known cancer-related gene mutations since actor Angelina Jolie shared her experience with genetic mutations and risk-reducing surgery in the media. In Korea, tests for germline BRCA1/2 mutations have been covered by insurance since May 2012 and the number of women of BRCA1/2 mutations has continued to increase over the past decade. Most carriers of BRCA1/2 mutations consider risk-reducing salpingo-oophorectomy (RRSO) resulting in early menopause and want to know the lifetime risks and benefits of RRSO. However, despite the increasing number of carriers of BRCA1/2 mutations, the counseling and management of patients requiring RRSO varies among physicians. This article provides basic knowledge on RRSO to help physicians comprehensively assess its risks and benefits and manage at-risk women.

참고문헌 (98)

  1. Gordon RS Jr, "An operational classification of disease prevention", Public Health Rep, 98, pp.107~109 (1983)
  2. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
  3. "Cancer statistics" (2023)[URL]
  4. Yun BS, "Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999-2019 : Korea Central Cancer Registry", Obstet Gynecol Sci, 66, pp.545~561 (2023)
  5. Hermsen BB, "No efficacy of annual gynaecological screening in BRCA1", 2 mutation carriers; an observational follow-up study, 2007, pp.96, 1335~1342
  6. Pinsky PF, "Potential effect of the risk of ovarian cancer algorithm(ROCA)on the mortality outcome of the prostate, lung, colorectal and ovarian(PLCO)trial", Int J Cancer, 132, pp.2127~2133 (2013)
  7. Buys SS, "Effect of screening on ovarian cancer mortality : the prostate, lung, colorectal and ovarian(PLCO)cancer screening randomized controlled trial", JAMA, 305, pp.2295~2303 (2011)
  8. Menon U, "Ovarian cancer prevention and screening", Obstet Gynecol, 131, pp.909~927 (2018)
  9. Liu YL, "Risk-reducing bilateral salpingooophorectomy for ovarian cancer : a review and clinical guide for hereditary predisposition genes", JCO Oncol Pract, 18, pp.201~209 (2022)
  10. Walsh T, "Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing", Proc Natl Acad Sci U S A, 108, pp.18032~18037 (2011)
  11. Carter NJ, "Germline pathogenic variants identified in women with ovarian tumors", Gynecol Oncol, 151, pp.481~488 (2018)
  12. Kuchenbaecker KB, "Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2mutation carriers", JAMA, 317, pp.2402~2416 (2017)
  13. Kauff ND, "Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation", N Engl J Med, 346, pp.1609~1615 (2002)
  14. Domchek SM, "Mortality after bilateral salpingooophorectomy in BRCA1 and BRCA2 mutation carriers : a prospective cohort study", Lancet Oncol, 7, pp.223~229 (2006)
  15. Kauff ND, "Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer : a multicenter, prospective study", J Clin Oncol, 26, pp.1331~1337 (2008)
  16. Eleje GU, "Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations", Cochrane Database Syst Rev, 8, pp.CD012464~ (2018)
  17. Finch AP, "Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation", J Clin Oncol, 32, pp.1547~ (2014)
  18. Carr CE, "Short-and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer", Int J Gynecol Cancer, 31, pp.215~221 (2021)
  19. Vermeulen RFM, "Impact of risk-reducing salpingo-oophorectomy in premenopausal women", Climacteric, 20, pp.212~221 (2017)
  20. Jung SM, "Trends in risk-reducing mastectomy and risk-reducing salpingo-oophorectomy in Korean carriers of the BRCA1", 2 mutation, 2020, pp.23, 647~655
  21. Kim SI, "Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers : experience at the National Cancer Center of Korea", J Cancer Res Clin Oncol, 142, pp.333~340 (2016)
  22. Metcalfe K, "International trends in the uptake of cancer risk reduction strategies in women with a BRCA1or BRCA2 mutation", Br J Cancer, 121, pp.15~21 (2019)
  23. Colombo N, "ESMO-ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†", Ann Oncol, 30, pp.672~705 (2019)
  24. "ACOG practice bulletin No. 103: hereditary breast and ovarian cancer syndrome", Obstet Gynecol, 113, pp.957~966 (2009)
  25. "Society of gynecologic oncologists clinical practice committee statement on prophylactic salpingo-oophorectomy", Gynecol Oncol, 98, pp.179~181 (2005)
  26. Mahe E, "Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma(STIC)in the"sectioning and extensively examining the FIMbriated end"(SEE-FIM)protocol?", Int J Gynecol Pathol, 32, pp.353~357 (2013)
  27. Tutt A, "The relationship between the roles of BRCA genes in DNA repair and cancer predisposition", Trends Mol Med, 8, pp.571~576 (2002)
  28. Park KS, "A population-based analysis of BRCA1", 2 genes and associated breast and ovarian cancer risk in Korean patients : a multicenter cohort study, 2021, pp.13, 2192~
  29. Antoniou A, "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history : a combined analysis of 22 studies", Am J Hum Genet, 72, pp.1117~1130 (2003)
  30. Kwon BS, "Clinical and genetic characteristics of BRCA1", 2mutation in Korean ovarian cancer patients : a multicenter study and literature review, 2019, pp.51, 941~950
  31. Daly MB, "NCCN guidelines® insights : genetic", familial high-risk assessment : breast, ovarian, and pancreatic, version 2. 2024, 2023, pp.21, 1000~1010
  32. Domchek SM, "Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality", JAMA, 304, pp.967~975 (2010)
  33. Yang X, "Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D", J Natl Cancer Inst, 112, pp.1242~1250 (2020)
  34. Suszynska M, "BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer : mutation prevalence and precise risk estimates based on a pooled analysis of~30, 000 cases", J Ovarian Res, 13, pp.50~ (2020)
  35. Song H, "Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population", J Clin Oncol, 33, pp.2901~2907 (2015)
  36. Suszynska M, "Large-scale meta-analysis of mutations identified in panels of breast", ovarian cancer-related genes-providing evidence of cancer predisposition genes, 2019, pp.153, 452~462
  37. Lilyquist J, "Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multigene panels compared to reference controls", Gynecol Oncol, 147, pp.375~380 (2017)
  38. Atchley DP, "Clinical and pathologic characteristics of patients with BRCA-positive and BRCAnegative breast cancer", J Clin Oncol, 26, pp.4282~4288 (2008)
  39. Song H, "The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population", Hum Mol Genet, 23, pp.4703~4709 (2014)
  40. Nair N, "Hysterectomy at the time of risk-reducing surgery in BRCA carriers", Gynecol Oncol Rep, 26, pp.71~74 (2018)
  41. Chen CC, "Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer", Annu Rev Cancer Biol, 2, pp.313~336 (2018)
  42. Parker WH, "Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’health study", Obstet Gynecol, 113, pp.1027~1037 (2009)
  43. Rocca WA, "Survival patterns after oophorectomy in premenopausal women : a population-based cohort study", Lancet Oncol, 7, pp.821~828 (2006)
  44. Gordhandas S, "Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits", Gynecol Oncol, 153, pp.192~200 (2019)
  45. Utian WH, "Impact of hormone therapy on quality of life after menopause", Menopause, 20, pp.1098~1105 (2013)
  46. Madalinska JB, "The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy", J Clin Oncol, 24, pp.3576~3582 (2006)
  47. Johansen N, "Sexual activity and functioning after riskreducing salpingo-oophorectomy : impact of hormone replacement therapy", Gynecol Oncol, 140, pp.101~106 (2016)
  48. Vermeulen RFM, "Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems : a prospective study", Eur J Cancer, 84, pp.159~167 (2017)
  49. Faubion SS, "Longterm health consequences of premature or early menopause and considerations for management", Climacteric, 18, pp.483~491 (2015)
  50. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society"Advisory Panel, "The 2022 hormone therapy position statement of The North American Menopause Society", Menopause, 29, pp.767~794 (2022)
  51. Atsma F, "Postmenopausal status and early menopause as independent risk factors for cardiovascular disease : a metaanalysis", Menopause, 13, pp.265~279 (2006)
  52. Rivera CM, "Increased cardiovascular mortality after early bilateral oophorectomy", Menopause, 16, pp.15~23 (2009)
  53. Rocca WA, "Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause", Neurology, 69, pp.1074~1083 (2007)
  54. Johansen N, "Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy", Acta Obstet Gynecol Scand, 96, pp.547~555 (2017)
  55. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women’s Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
  56. Manson JE, "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials", JAMA, 310, pp.1353~1368 (2013)
  57. Chlebowski RT, "Breast cancer after use of estrogen plus progestin in postmenopausal women", N Engl J Med, 360, pp.573~587 (2009)
  58. Holmberg L, "Increased risk of recurrence after hormone replacement therapy in breast cancer survivors", J Natl Cancer Inst, 100, pp.475~482 (2008)
  59. Rebbeck TR, "Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2mutation carriers : the PROSE Study Group", J Clin Oncol, 23, pp.7804~7810 (2005)
  60. Eisen A, "Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers", J Natl Cancer Inst, 100, pp.1361~1367 (2008)
  61. Kotsopoulos J, "Hormone replacement therapy after menopause and risk of breast cancer in BRCA1mutation carriers : a case-control study", Breast Cancer Res Treat, 155, pp.365~373 (2016)
  62. Kotsopoulos J, "Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1mutation carriers", JAMA Oncol, 4, pp.1059~1065 (2018)
  63. Kaunitz AM, "Surgical menopause : health implications and hormonal management", Menopause, 28, pp.1~3 (2020)
  64. Ettinger B, "Cyclic hormone replacement therapy using quarterly progestin", Obstet Gynecol, 83, pp.693~700 (1994)
  65. Andersson K, "Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy", Obstet Gynecol, 79, pp.963~967 (1992)
  66. Chapman JS, "Surveillance of survivors : follow-up after risk-reducing salpingo-oophorectomy in BRCA 1", 2mutation carriers, 2011, pp.122, 339~343
  67. Mahdavi M, "Hereditary breast cancer;genetic penetrance and current status with BRCA", J Cell Physiol, 234, pp.5741~5750 (2019)
  68. Wang Y, "Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1or BRCA2 mutation carriers : a systematic review and meta-analysis", Eur J Surg Oncol, 48, pp.1209~1216 (2022)
  69. Rebbeck TR, "Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers", J Natl Cancer Inst, 91, pp.1475~1479 (1999)
  70. Mai PL, "Risk-reducing salpingo-oophorectomy and breast cancer risk reduction in the gynecologic oncology group protocol-0199(GOG-0199)", JNCI Cancer Spectr, 4, pp.pkz075~ (2019)
  71. Stjepanovic N, "Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1", 2 mutation carriers : maximising bias-reduction, 2020, pp.132, 53~60
  72. Lakhani SR, "The pathology of familial breast cancer : predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2", J Clin Oncol, 20, pp.2310~2318 (2002)
  73. Mavaddat N, "Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk : an international prospective cohort of BRCA1 and BRCA2 mutation carriers", Breast Cancer Res, 22, pp.8~ (2020)
  74. Bachelier R, "Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice", Oncol Rep, 14, pp.1117~1120 (2005)
  75. Poole AJ, "Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist", Science, 314, pp.1467~1470 (2006)
  76. van de Ven M, "BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling", J Pathol, 246, pp.41~53 (2018)
  77. Harmsen MG, "Peritoneal carcinomatosis after riskreducing surgery in BRCA1", 2 mutation carriers, 2018, pp.124, 952~959
  78. Finch A, "Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation", JAMA, 296, pp.185~192 (2006)
  79. Carlson JW, "Serous tubal intraepithelial carcinoma : its potential role in primary peritoneal serous carcinoma and serous cancer prevention", J Clin Oncol, 26, pp.4160~4165 (2008)
  80. Zakhour M, "Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers", Gynecol Oncol, 143, pp.231~235 (2016)
  81. Sherman ME, "Pathologic findings at risk-reducing salpingo-oophorectomy : primary results from gynecologic oncology group trial GOG-0199", J Clin Oncol, 32, pp.3275~3283 (2014)
  82. Patrono MG, "Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma(STIC) : a comprehensive review", Gynecol Oncol, 139, pp.568~572 (2015)
  83. Steenbeek MP, "Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy : a systematic review and individual patient data metaanalysis", J Clin Oncol, 40, pp.1879~1891 (2022)
  84. Powell CB, "Risk-reducing salpingo-oophorectomy(RRSO)in BRCA mutation carriers : experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol", Int J Gynecol Cancer, 21, pp.846~851 (2011)
  85. Finch A, "Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers", Gynecol Oncol, 100, pp.58~64 (2006)
  86. Conner JR, "Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations", Gynecol Oncol, 132, pp.280~286 (2014)
  87. Manchanda R, "Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status", BJOG, 118, pp.814~824 (2011)
  88. Weiss JM, "NCCN guidelines® insights : genetic", familial high-risk assessment : colorectal, version 1. 2021, 2021, pp.19, 1122~1132
  89. Shu CA, "Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations", JAMA Oncol, 2, pp.1434~1440 (2016)
  90. de Jonge MM, "Linking uterine serous carcinoma to BRCA1", 2-associated cancer syndrome : a meta-analysis and case report, 2017, pp.72, 215~225
  91. Havrilesky LJ, "Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingooophorectomy for prophylaxis against serous", serouslike uterine cancers in BRCA1 mutation carriers, 2017, pp.145, 549~554
  92. Segev Y, "Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation : a case control study", Fam Cancer, 14, pp.383~391 (2015)
  93. Pickett CM, "Surgical approach to hysterectomy for benign gynaecological disease", Cochrane Database Syst Rev, 8, pp.CD003677~ (2023)
  94. Kwon JS, "Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome", Cancer, 113, pp.326~335 (2008)
  95. Boerner T, "Salpingectomy for the risk reduction of ovarian cancer : is it time for a salpingectomyalone approach?", J Minim Invasive Gynecol, 28, pp.403~408 (2021)
  96. Holman LL, "Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers", Gynecol Oncol, 133, pp.283~286 (2014)
  97. Harmsen MG, "Early salpingectomy(TUbectomy)with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1", 2 mutation carriers(TUBA study) : a prospective non-randomised multicentre study, 2015, pp.15, 593~
  98. Steenbeek MP, "TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention : the TUBA-WISP II study protocol", Int J Gynecol Cancer, 33, pp.982~987 (2023)

관련 논문AI추천

Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study김세익, 설애란, 이광빈, 임현지, 현소운, 이마리아연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제12호Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers강한성, 강혁조, 공선영, 박보람, 박보영, 박상윤, 박수진, 이시연, 이은경, 이은숙, 임명철, 정소연, 주정남, 한재홍대한암학회 · Cancer Research and Treatment2019 · 제51권 제1호Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea김동원, 김성원, 김지영, 박보영, 윤정현, 이봄이대한암학회 · Cancer Research and Treatment2022 · 제54권 제2호Factors associated with the decision to undergo risk-reducing salpingo-oophorectomy among women at high risk for hereditary breast and ovarian cancer: a systematic review김수, 김유림, 박선영한국여성건강간호학회 · Women's Health Nursing2020 · 제26권 제4호Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea김혜연, 문석주, 박지수, 이재관, 정소현, 조금준, 조현웅, 홍진화대한암학회 · Cancer Research and Treatment2024 · 제56권 제1호Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review권병수, 김기형, 변정미, 서동수, 신경화, 이태화, 이현주, 정대훈대한암학회 · Cancer Research and Treatment2019 · 제51권 제3호

이 간행물의 다른 논문 (9건)

Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysisSapiyat Isaeva, Ekaterina Krylova, Leila Adamyan, Lilia Obosyan, Laura Pivazyanpp. 356-379The influence of advanced maternal age on congenital malformations, short- and long-term outcomes in offspring of nulligravida: a Korean National Cohort Study over 15 yearsSoo-Young Oh, Cheong-Rae Roh, Suk-Joo Choi, Juhee Cho, Danbee Kang, Su Jin You, Ji-Hee Sung, Hyejeong Parkpp. 380-392Prenatal diagnosis and postnatal outcome of fetal intracranial hemorrhage: a single-center experienceYun Ji Jung, 김영한, Suhra Kim, 권자영, Jiwon Baik, Hayan Kwon, 이준호pp. 393-403Living lab modelling as a pilot study assessing the potential psychological health benefits of forest environment for cancer survivorsMi-Kyung Kim, Hyo Jin Park, Kyung Ju Leepp. 404-413Evaluation of oxidative stress and inflammation in patients with polycystic ovary syndromeSenem Gonultas, Berra Sen, Ilgar Acar, Muserref Banu Yilmaz, Ebru Kale, Eray Metin Guler, Havva Sevde Islek, Beyza Nur Ozkan, Sevval Temur, Ceren Albayrakpp. 414-420
원문 보기